Last Updated on: 5th March 2024, 04:27 pm
Cancan Diagnostic is delighted to announce the launch of K9-LiquiDX, marking the advent of the first-ever Minimal Residual Disease (MRD) test engineered specifically for dogs. Set to be released on March 5, 2024, K9-LiquiDX embodies a significant stride in veterinary oncology, equipping vets and pet owners with an advanced tool for the early detection of cancer relapse and meticulous disease management. By pinpointing the elusive cancer cells that may elude conventional diagnostic methods post-treatment, K9-LiquiDX is set to redefine cancer treatment paradigms in dogs.
Conceived by a consortium of preeminent scientists and veterinary oncology experts, K9-LiquiDX harnesses sophisticated molecular diagnostics to uncover the subtlest signals of cancer recurrence. This test’s exceptional sensitivity ensures the earliest possible detection of relapse, enabling prompt and customised therapeutic interventions. K9-LiquiDX is poised to significantly enhance our capability to track the effectiveness of cancer treatments and modify treatment plans to better the prognosis for our canine friends.
The principal benefits of K9-LiquiDX include:
- Early Relapse Detection: Empowers veterinary professionals to detect the early stages of cancer relapse, possibly before the onset of observable symptoms.
- Precision Cancer Monitoring: Offers an in-depth view of the cancer’s trajectory and responsiveness to treatments, allowing for more individualised and efficacious management plans.
- Enhanced Treatment Strategies: Supports informed decision-making regarding treatment modifications, with the potential to improve survival rates and the quality of life for dogs afflicted with cancer.
Dr. Maciej Parys, CEO of Cancan Diagnostic, commented on the impact of this breakthrough, stating, “K9-LiquiDX is more than just a diagnostic test; it has a potential to revolutionise how we monitor dogs with cancer and help them and their families through improvement of their quality of life. By focusing on early relapse detection and precision monitoring, we’re opening new pathways for personalised cancer care in veterinary medicine. This test is a testament to our commitment to pioneering advancements that make a real difference in the lives of pets and their owners.”
K9-LiquiDX will become available to veterinary clinics across the UK from March 5, 2024, with Cancan Diagnostic committed to providing extensive support and educational resources to facilitate the integration of this innovative test into cancer care regimens.
Cancan Diagnostic has consistently led the way in veterinary diagnostic innovation since its foundation in 2022. With a mission to enhance pet healthcare through the integration of state-of-the-art science and technology in veterinary settings, the launch of K9-LiquiDX underscores the company’s role as a frontrunner in veterinary oncology and its unwavering commitment to improving pet health outcomes.
